Mark Saad

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Mark Saad

Mark Saad was last confirmed as CFO and Board Member at Axsome Therapeutics, Inc. (AXSM) in a filing dated April 21, 2020. Axsome Therapeutics, Inc. reported in an 8-K filed June 8, 2023 that Mark Saad was appointed Class II Director, effective June 2, 2023.

“The Company's stockholders elected the following director to serve as a Class II director until the 2026 annual meeting of stockholders and until their successor is duly elected and qualified.”

Axsome Therapeutics, Inc. Form 8-K, filed June 8, 2023 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Research with Equibles

Turn this profile into a cited research brief

Start with a question tailored to the filings and events on this page, or connect Equibles financial data to ChatGPT or Claude.

Suggested question: “Summarize Mark Saad's recent executive appointments or departures and cite the source filings.”

Use in your AI

Affiliation history

Recorded current and former roles; source labels appear when available.

Axsome Therapeutics, Inc. (AXSM)
CFO

Proxy statement

Start not stated–2020-04-21

Last confirmed by a filing; no departure on record
Axsome Therapeutics, Inc. (AXSM)
Board Member

Proxy statement

Start not stated–2020-04-21

Last confirmed by a filing; no departure on record

Company network

Recorded roles and call appearances connecting this person to public companies.

Axsome Therapeutics, Inc.

AXSM

CFO, Board Member

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.

Executive change Appointed: Class II Director Axsome Therapeutics, Inc. (AXSM)
2023-06-02